Immunotherapies offer the potential to reprogramme immune system halt autoimmune destruction of insulin-producing β-cells within pancreas, dealing with root cause type 1 diabetes (T1DM) for first time. Leading on from this, teplizumab, drug in this class, has been found delay onset T1DM by an average three years people stratified high risk developing T1DM. This review will critically consider e...

Thyroid Eye disease is a potentially vison impairing condition for which Teprotumumab has emerged as premier option in managing activity. The primary mechanism of action monoclonal antibody against the insulin-like growth factor-I receptor but large portion remains unknown. In original trial about 10% patients developed hyperglycemia was described self limited and mild. Since commercial release...

The International Diabetes Federation estimates that approximately 0.4% of the Belgian population is diagnosed with type 1 diabetes mellitus, which is similar to other industrialized countries. The prevalence of transgenderism is estimated at 0.6% to 0.7% of all adults in Western populations. In this study, we evaluated whether there was an increased prevalence of type 1 diabetes mellitus in tr...

The relationship between autoimmune diabetes or type 1 diabetes mellitus and vitamin D has been reported in the literature. Many factors, environmental and genetic, have been known, as risk factors, to cause both type 1 diabetes and vitamin D deficiency. Vitamin D treatment has improved or prevented type 1 diabetes mellitus in animals and humans. Vitamin D also has been known to protect from au...